This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ICT-107

ImmunoCellular Therapeutics, Ltd.

Drug Names(s): ICT-107

Description: ICT-107 is a dendritic cell-based therapeutic vaccine that consists of dendritic cells loaded with the tumor antigens HER2, TRP-2, gp100, MAGE-1, IL13Ra2, and AIM-2.

Deal Structure: ImmunoCellular and University of Pennsylvania
In April 2010, ImmunoCellular announced has entered into a sponsored research agreement and an option agreement with The University of Pennsylvania (UPENN) to support process development and manufacturing in a planned Phase II clinical trial of ICT-107 for the treatment of glioblastoma multiforme (GBM).

In February 2012, ImmunoCellular it entered into an agreement with the University of Pennsylvania under which University of Pennsylvania has granted the Company an exclusive, worldwide license for a patent pending technology for the production of high-activity dendritic cells (DCs). The license covers the application of this technology to the development of therapeutics for all indications except breast cancer and ductal carcinoma in situ. The licensed technology underlies ICT-107. The terms of the agreement were not disclosed.


ICT-107 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug